Hims Hers Health Inc (HIMS)vsMerck & Company Inc (MRK)
HIMS
Hims Hers Health Inc
$27.51
+0.26%
HEALTHCARE · Cap: $6.57B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2482% more annual revenue ($66.57B vs $2.58B). MRK leads profitability with a 4.8% profit margin vs -5.5%. HIMS appears more attractively valued with a PEG of 2.53. HIMS earns a higher WallStSmart Score of 37/100 (F).
HIMS
Hold37
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.7%
Fair Value
$27.16
Current Price
$27.51
$0.35 premium
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.2% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Trading at 19.8x book value
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Revenue Growth. Revenue growth of 38.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
HIMS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.41 — expect wider price swings.
HIMS is growing revenue faster at 38.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
HIMS scores higher overall (37/100 vs 36/100) and 38.2% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?